Solid Biosciences Doses First Phase 3 Duchenne Participant, Holds $380.7M Cash Runway
Solid Biosciences held $380.7 million in cash and equivalents, extending its runway into H1 2028, and dosed the first participant in its Phase 3 IMPACT DUCHENNE trial for SGT-003, which secured EMA positive pediatric investigation plan opinion and European Commission orphan designation. The company dosed a second Friedreich’s ataxia Phase 1b participant.
1. First Quarter Financial Position
Solid Biosciences ended Q1 2026 with $380.7 million in cash, cash equivalents and available-for-sale securities, providing a projected cash runway into the first half of 2028. This financial position underpins ongoing development across its neuromuscular and cardiac gene therapy programs.
2. Duchenne Program Advancement
In its Duchenne muscular dystrophy pipeline, Solid dosed the first patient in the Phase 3 IMPACT DUCHENNE trial evaluating SGT-003 on May 7, 2026, and received a positive pediatric investigation plan opinion from the EMA along with European Commission orphan drug designation, accelerating global program alignment.
3. Friedreich’s Ataxia Trial Progress
The Friedreich’s ataxia gene therapy SGT-212 program achieved dosing of its second participant in the Phase 1b FALCON trial, reporting no serious adverse events to date. Participant enrollment continues, with initial safety and tolerability data anticipated by year-end 2026.
4. CPVT Program and Upcoming Milestones
For its CPVT program, the company has activated trial sites and expects to enroll the first patient in the Phase 1b ARTEMIS trial in the second half of 2026, targeting initial safety data in H1 2027. Solid also plans to strengthen its ex-U.S. leadership team to support global development.